Cloud Computing and Analytics in Pharma


Published on

Solving the problems of unstructured data and high R&D costs in the pharma industry through the use of Cloud computing and Analytics

Published in: Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Cloud Computing and Analytics in Pharma

  1. 1. Solving the problem of disjointed information and high R&D costs Nihar Routray BLP022
  2. 2. The ChallengeNeed for a practical solution to tackle the twin problems of disjointed information andextremely high R&D costs for a multi-national and multi-brand company.  R & D in a pharmaceutical company is a very complex process requiring considerable amount of time and a diverse set of stand-alone systems and specialized computer applications. The requirement of resources for these applications has become so high now that the company cannot afford the considerable costs of building, implementing and supporting these infrastructures.  Pharmaceutical companies generally face the problem of having complex silos of information built around their brands. Along with that large amount of information is being created everyday by numerous systems and applications in all kinds of formats which pose a serious challenge to manage, monitor and retrieve required information at times of need.  Being a large multi-national, though the company employs advanced communication systems but still a significant disconnect is observed between the various enterprise teams as they are dispersed across different global locations.  Pharma companies also need to maintain their legacy systems containing critical data as the FDA requires data related to a drug to be maintained for a minimum period of 2 years after it was last sold. Due to this the legacy systems cannot be completely done away with and integrating them will run into huge costs.Assumption:Have considered a pharmaceutical company which is spread across different geographies acrossthe world and has multiple brands in its drug portfolio
  3. 3. Current Situation Currently, the company is just throwing in more resources, people, computational and storage capabilities at the problem. However, this approach cannot be continued with and is economically unviable in today’s world of cut-throat competition and economic climate. Now let us understand the R&D process and how IT has been supporting it.DISCOVERY Pre Discovery Aim: Understand the disease and choose target molecule Process: Scientists from government, industry and academic institutes create knowledge base using various computational tools and insights Discovery Aim: Find Lead compound 3-6 Years Process: High Throughput screening via robotics and computational power, De Novo creation, Genetic engineering Pre-Clinical Aim: Determine drug is safe for testing in human beings Process: Extensive in vitro and in vivo tests and recording of test dataDEVELOPMENT IND Aim: Obtain approval from FDA for clinical trials in human beings Process: Review by FDA and IRB 6-7 Years Clinical Trials Aim: Trials in human being to check drug efficacy, dosage and safety Process: Drug tested on human beings in 3 phases moving from smaller to larger patient groups. Trial data recorded on paper or through LIMS Review Aim: Review by FDA for drug approval and manufacturing Process: FDA reviews the NDA which can be more than 100000 pages 1-2 Years Manufacturing Aim: Large scale manufacturing of drug Process: Scaling up facility and large scale production following GMP Ongoing Studies Aim: Monitor drug in market Process: Monitor the drug in market and report adverse events to FDA Estimates Cost: Upto 1 Billion Duration: 10-15 years
  4. 4. All the steps mentioned above include a huge number of activities and consume a lot of time toget completed. A variety of dedicated systems are employed at each stage to support processesand record and manage the data being generated.As we saw in the process flow, a new drug development costs around $1 billion and takes aminimum of 10 years to complete. Also, a large number of potential drug research projects areshelved at some point during the drug development process owing to adverse effects or limitedefficacy. According to Industry records, only 1 out of 1,000 potential compounds get approvedfinally and are sold in the market.The company is currently getting inundated with complicated and resource intensiveapplications which are churning out huge amount of data. So, the company is hard pressed todo more with less while increasing flexibility and responsiveness to meet the business needs.The IT budgets of Pharma companies are nearly consuming 15% of the total R&D expendituresand about 8% of the total headcount of the organization. This high level of resourceconsumption while maybe essential but does move the organization away from its core missionof drug discovery and development.So it becomes highly imperative for the company to find ways to reduce R&D costs while at thesame time increasing productivity through better data management and retrieval.Approach HighlightsHappiest Minds proposes a two pronged approach of embedding analytics into its dailyoperations while leveraging the cloud to counter the problems of disjointed information andhigh R&D costs. This approach would be carefully implemented along with an informationagenda as it would provide a high level roadmap aligning the business needs with the analyticinsight and the cloud platform to the underlying technology and processes.The company will be provided with an access to a low-cost shared cloud computingenvironment with an array of hardware, software and technical resources which would helpreduce the various costs. Our cloud platforms will help you integrate your entire businessservices and include high levels of shared data management and advanced features to help youadopt new business models which would clearly differentiate your organization from the rest in
  5. 5. the industry. These cloud platforms are also encompassed in a layer of security frameworkwhich would take care of all the perceived risks. There would be further reduction in costs as allthe heavy functions such as computing power and storage will be leveraged in the cloud.Proportion of Life Sciences R&D Informatics budget devoted to Cloud computing in 3 years:Source: Insight Pharma ReportsThe augmented analytics capabilities provide end users access to near real-time informationfacilitating collaboration and preserving transparency. The differentiated analytics advantageprovided by Happiest Minds will help the company achieve value creation quite early in anorganization’s progression to sophistication by leveraging structured and unstructured datafrom within and outside the organization.Source: Analytics: The New Path to Value, a joint MIT Sloan Management Review and IBM Institute for Business Value study.Copyright © Massachusetts Institute of Technology 2010.
  6. 6. Why Happiest MindsCompanies are seizing this opportunity provided by Happiest Minds to use advancedinformation analytics and cloud computing for business advantage in their respective industrysectors. These business leaders are not depending anymore only on intuition but are combiningthe new analytics techniques with the expertise from Happiest Minds to make decisions in acompletely different way. Creating disruptions through technology as well as through the next generation skilled worker